Over 50 combined years of medical practice and product innovation

Leadership Team

evan_unger_0.jpg

Evan C. Unger, MD, FACR

Interim Chief Executive Officer

Evan Unger M.D. is a renowned expert on ultrasound contrast media. He founded MVT to advance the field of ultrasound contrast agents and theranostics. Dr. Unger has also founded three other biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs, including Definity®, the world’s #1 selling ultrasound contrast agent. ImaRx Pharmaceutical was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using ultrasound and microbubbles to treat ischemic stroke. Dr. Unger co-founded NuvOx, a clinical-stage biotech company that is in Phase II trials for stroke and brain cancer. He is a co-inventor on the issued U.S. patent covering MVT-100 and also an inventor on over 120 other issued US patents. He is a board-certified radiologist and has had an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona and serves as President and CEO of NuvOx Pharma. 

emmanuelle_meuillet1.jpg

Emmanuelle J. Meuillet, PhD

Chief Scientific Officer

Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development.  Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France).  She has had an appointment as an Associate Professor at the University of Arizona.  Over the years, Dr. Meuillet has managed many NIH funded programs in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects.  She founded two biotech companies, PHusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules.  Dr. Meuillet is a consultant for the NIH and DoD. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on five patents and she belong to several editorial boards for specialized cancer journals. She joined Microvascular Therapeutics in 2018. 

201210028_unger_wyatt_4x6_dsc4033_0.jpg

Wyatt Unger, MD, MBA

Chief Medical Officer

Dr. Unger received his B.A. in economics from Northwestern University, M.D. from the University of Arizona College of Medicine with Alpha Omega Alpha honors, and MBA from the University of Arizona Eller College of Business.  Dr. Unger completed diagnostic radiology residency training at Arizona, where he also completed a fellowship in Abdominal MRI imaging. Dr. Unger has authored multiple peer-reviewed abstracts and journal publications, worked as a consultant in clinical development and clinical trial design for Nuvox Pharmaceutical and serves as the Chief Medical Officer for Microvascular Therapeutics where he is overseeing clinical development and clinical trial design for their pharmaceutical candidate MVT-100.

201210028_unger_wyatt_4x6_dsc4033_0.jpg

Wyatt Unger, MD, MBA

Chief Medical Officer

Dr. Unger received his B.A. in economics from Northwestern University, M.D. from the University of Arizona College of Medicine with Alpha Omega Alpha honors, and MBA from the University of Arizona Eller College of Business.  Dr. Unger completed diagnostic radiology residency training at Arizona, where he also completed a fellowship in Abdominal MRI imaging. Dr. Unger has authored multiple peer-reviewed abstracts and journal publications, worked as a consultant in clinical development and clinical trial design for Nuvox Pharmaceutical and serves as the Chief Medical Officer for Microvascular Therapeutics where he is overseeing clinical development and clinical trial design for their pharmaceutical candidate MVT-100.

Board of Directors

Evan C Unger, MD   
Chairman of the Board                             
 

Timothy Healey, BS, MBA
Mr. Healey’s executive experience includes serving as Chief Commercial Officer - Complete Commercialization at EVERSANA™, Senior Vice President, Commercial at Lantheus Medical Imaging, Vice President/General Manager for US Virology at Abbott Laboratories/AbbVie, Senior Vice President, Commercial at AMAG Pharmaceuticals, and Executive Director of CNS Marketing at Sepracor. During his tenure at Lantheus, Mr. Healey was responsible for worldwide sales and marketing of Definity®, the #1 selling ultrasound contrast agent. At Sepracor, Mr. Healey orchestrated the launch of Lunesta® (Sleep), one of the most successful launches to date, generating more than 4 million prescriptions in the first year of launch. He has also played key roles in the launches of Feraheme ® (Nephrology), as well as new indications for Allegra® (Allergy). He has won prestigious awards for launch excellence including Brandweek’s “Marketer of the Year,” and Medical Marketing a Media’s “Brand Team of the Year.” Mr. Healey received a Bachelor of Science degree from Boston College, and a Masters in Business Administration from Babson College where he was inducted into the Beta Gamma Sigma Scholastic Honorary Society.
 

Tim Healey Headshot.jpg
Shiv Kapoor, BA, MBA
Shiv Kapoor has over 25 years of experience in business strategy, finance, investments, investor relations, research and regulatory fields in companies such as Johnson & Johnson, Citigroup, Montgomery & Co., Alza Corporation, and Spectrum Pharmaceuticals. He is also the founder of cancer focused biotechnology company, BioRamon Pharmaceuticals. Mr. Kapoor has been a top ranked analyst on both the buy and sell sides of Wall Street. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. Mr. Kapoor holds a BA in Biochemistry UC Berkeley, and an MBA from The University of Chicago Booth School of Business.
M Rosenberg.jpg

Board of Scientific Advisors

Marty Rosenberg
Dr. Rosenberg is a graduate of Temple University School of Medicine and trained in general surgery at Albert Einstein Medical Center in Philadelphia.  He joined Squibb Diagnostics in 1990 and worked on the clinical development and approval of two novel oral contrast agents from ImarX pharmaceuticals: SonoRx and LumenHance.   In 1996, he was hired by Bristol-Myers Squibb Medical Imaging, formerly DuPont Pharma, to develop the ultrasound contrast agent Definity (DMP-115), also invented by Imarx pharmaceuticals.  Dr. Rosenberg is currently working for Bayer Radiology where he led the initial approval and additional indications for Gadavist in the US.